Analysts' ratings for Eli Lilly LLY over the last quarter vary from bullish to bearish, as provided by 8 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 6 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 4 | 1 | 0 | 0 |
Analysts have set 12-month price targets for Eli Lilly, revealing an average target of $635.88, a high estimate of $722.00, and a low estimate of $535.00. Observing a downward trend, the current average is 2.4% lower than the prior average price target of $651.50.
Interpreting Analyst Ratings: A Closer Look
In examining recent analyst actions, we gain insights into how financial experts perceive Eli Lilly. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Carter Gould | Barclays | Raises | Overweight | $680.00 | $630.00 |
| Eli Lilly | Daiwa Capital | Announces | Outperform | $610.00 | - |
| Robyn Karnauskas | Truist Securities | Maintains | Buy | $650.00 | - |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $630.00 | - |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $630.00 | - |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $630.00 | - |
| James Shin | Deutsche Bank | Announces | Hold | $535.00 | - |
| David Phung | Morgan Stanley | Raises | Overweight | $722.00 | $673.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Eli Lilly. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Eli Lilly compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Eli Lilly's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Eli Lilly's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Eli Lilly analyst ratings.
Unveiling the Story Behind Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Financial Milestones: Eli Lilly's Journey
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Eli Lilly displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 36.84%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -0.6%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Eli Lilly's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -0.52%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Eli Lilly's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.1%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Eli Lilly's debt-to-equity ratio stands notably higher than the industry average, reaching 1.8. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Understanding the Relevance of Analyst Ratings
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
